trial · primary record
Pegozafermin
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1350 |
| Primary completion | 2029-02 |
| Primary endpoint | Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52 |
| Registry ID | NCT06318169 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:09.353Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06318169
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.